NEW YORK (GenomeWeb News) – In a blow to Sequenom, a federal court has invalidated a patent held by the company covering the detection of cell-free DNA in the bloodstream of pregnant women.

On Wednesday, the US District Court for the Northern District of California granted Ariosa Diagnostics summary judgment and invalidated US Patent No. 6,258,540, saying the patent covers a phenomenon of nature, which is unpatentable.

Sequenom holds an exclusive license to the '540 patent, which underlies its MaterniT21 Plus non-invasive prenatal diagnostic test, from Isis Innovations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: locus linked to non-syndromic hearing loss, phylogenetic relationships of Klebsiella pneumoniae isolates, and more.

In a column at Nature, researcher Fyodor Kondrashov worries about the influence of politics on Russian science.

The term 'epigenetics' is being used by quacks to give them a veneer of science, writes Adam Rutherford at the Observer.

The NIH has issued a preliminary guidance for newborn dried blood spot research.